scispace - formally typeset
D

Daniel E Jonas

Researcher at University of North Carolina at Chapel Hill

Publications -  129
Citations -  8426

Daniel E Jonas is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Randomized controlled trial & Psychological intervention. The author has an hindex of 37, co-authored 114 publications receiving 7272 citations.

Papers
More filters
Journal ArticleDOI

Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings A Systematic Review and Meta-analysis

TL;DR: In this paper, the authors compared acamprosate to naltrexone and found no statistically significant difference between them for return to any drinking (RD, 0.14 to 0.03) or heavy drinking.
Journal ArticleDOI

Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis:

TL;DR: Evidence supports efficacy of exposure therapy including the manualized version Prolonged Exposure (PE); cognitive therapy (CT), cognitive processing therapy (CPT), cognitive behavioral therapy (CBT)-mixed therapies ( moderate SOE); eye movement desensitization and reprocessing (EMDR) and narrative exposure therapy (low-moderate SOE).
Journal ArticleDOI

Transitional Care Interventions to Prevent Readmissions for Persons With Heart Failure: A Systematic Review and Meta-analysis

TL;DR: A systematic review of transitional care interventions for persons with HF for the Effective Health Care Program of the Agency for Healthcare Research and Quality (AHRQ) and a broad range of intervention types applicable to adults transitioning from hospital to home that aimed to prevent readmissions are conducted.

Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings

TL;DR: A systematic review and meta-analysis of the benefits and harms of medications for adults with alcohol use disorders found moderate evidence supports an association with improvement in some consumption outcomes for nalmefene and topiramate.
Journal Article

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

TL;DR: Meta-analyses of placebo-controlled data support the drugs’ modest overall benefits for stabilizing or slowing decline in cognition, function, behavior, and clinical global change.